ClinicalTrials.gg
CompletedNCT06259526Updated Nov 19, 2025

A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

A Phase 2 interventional study of Placebo group and JS1-1-01 low-dose group in Depression, sponsored by Tasly Pharmaceutical Group Co., Ltd. Completed at 17 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Enrollment
67th of 284
267 · median 129
Started
2023
with 43 others
Phase 2
11 of 358
2 open now
Registered
206th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 67th largest by enrollment of the 284 interventional ones that give a count, is one of 44 that started in 2023, is one of 11 in phase 2, and was the 206th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,098 Depression studies recruiting now, 473 (43%) set no upper age limit and 524 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All of the following standards must be met:

    1. Age range from 18 to 65 years old (including boundary values), both male and female;
    2. Single or recurrent episodes (296.2/296.3) that meet the diagnostic criteria for depression in (Diagnostic and Statistical Manual of Mental Disorders, 5th edition);
    3. During the screening and baseline periods, the total score of the Montgomery Asperger Depression Rating Scale (MADRS) was ≥ 26 points;
    4. Screening and baseline periods, with a Clinical Global Impression Scale Disease Severity (CGI-S) score of ≥ 4 points;
    5. Voluntary participation in clinical trials, able to sign forms, and able to understand and comply with research procedures.

Exclusion criteria

Exclusion Criteria:

  • Those who meet any of the following criteria cannot be included in this experiment:

    1. Individuals with a history of severe drug allergies or allergies to Piper Piper (pepper plant) or Duloxetine;
    2. Those who have used at least two antidepressants in sufficient dosage and duration (treated according to the maximum dosage in the instructions for at least 4 weeks) in a single or current episode in the past but still have no effect;
    3. Those who have been ineffective in using Duloxetine in sufficient amounts during the previous treatment course;
    4. The patients of depression secondary to other mental or physical illnesses;
    5. Patients of depression with accompanying psychiatric symptoms;
    6. Significant suicidal attempt or behavior within the past year, with a score of ≥ 3 on the 10th item (suicidal ideation) of the MADRS scale;
    7. During the baseline period, those with a reduction rate of ≥ 25% in the MADRS scale score compared to the screening period;
    8. Individuals with a history of epileptic seizures (excluding convulsions caused by febrile seizures in children);
    9. Individuals who have received depression related systemic physical therapy within 3 months prior to their first administration: modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), phototherapy, or systemic psychotherapy;
    10. Systematically receiving antidepressant treatment within the first 2 weeks of randomization, or discontinuing antidepressant medication for less than 5 half-lives before randomization;
    11. Individuals with severe unstable cardiovascular disease, liver disease, kidney disease, blood disease, endocrine disease, and other physical diseases or medical history;
    12. Accompanied by a history of malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);
    13. Screening or baseline abnormalities that have clinical significance and are deemed unsuitable for inclusion by investigators, such as male ≥ 450 ms, female QTcF ≥ 470 ms, or having a history of long QT syndrome;
    14. A history of symptomatic orthostatic hypotension (i.e. orthostatic syncope) with clinical significance;
    15. During the screening or baseline period, is above 2 times the value, and or AST is above 2 times the upper limit of normal value; Cr is higher than 1.2 times the upper limit of normal value;
    16. Thyroid dysfunction (TSH above 1.2 times the upper limit of normal value or below 0.8 times the lower limit of normal value) or the presence of hyperthyroidism or hypothyroidism determined by the investigators;
    17. Individuals with a history of elevated intraocular pressure or narrow angle glaucoma;
    18. Screening period, drug abuse screening positive individuals;
    19. A history of alcohol dependence within one year prior to screening;
    20. Pregnant and lactating women, male or female subjects who have a family planning or are unable to take effective measures within 30 days after signing the form and ending the trial;
    21. Screening for individuals who have participated in clinical trials and taken drugs within the first 30 days;
    22. The investigators believe that the subjects have poor compliance or there are other clinical, social, or family factors that are not suitable for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Drug: Placebo group

  • Experimental
    JS1-1-01 low-dose group

    Drug: JS1-1-01 low-dose group

  • Experimental
    JS1-1-01 medium dose group

    Drug: JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules

  • Experimental
    JS1-1-01 high-dose group

    Drug: JS1-1-01 high-dose group

  • Active comparator
    Active drug group

    Drug: Active drug group

Interventions

  • DrugPlacebo group

    (1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules

  • DrugJS1-1-01 low-dose group

    (1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules

  • DrugJS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules

    (1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 pills; JS1-1-01 placebo pills

  • DrugJS1-1-01 high-dose group

    (1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 pills; Duloxetine hydrochloride placebo capsules

  • DrugActive drug group

    (1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.

    Also known as: JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule

06

What researchers measure

Primary outcomes

  1. The change in MADRS total score from baseline

    There are a total of 10 projects in Montgomery-Asberg Depression Rating Scale(MADRS), each with a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

Secondary outcomes

  1. The change in HAMD-17 total score from baseline

    There are a total of 17 projects in Hamilton Depression Scale-17(HAMD-17). Scores are distributed on a scale of 0 to 53. A score above 24 indicates severe depression, a score of 17 indicates moderate depression, and a score below 7 indicates no depressive symptoms.

    Time frame: 8 weeks

  2. The effective rate of MADRS

    The effective definition of MADRS is that the reduction rate of MADRS score relative to baseline is ≥ 50%.

    Time frame: 8 weeks

  3. The effective rate of HAMD-17

    The effective definition of HAMD-17 is that the reduction rate of HAMD-17 score relative to baseline is ≥ 50%.

    Time frame: 8 weeks

  4. The response rate of MADRS

    The response definition of MADRS is that the score ≤ 12 points.

    Time frame: 8 weeks

  5. The response rate of HAMD-17

    The response definition of HAMD-17 is that the score ≤ 7 points.

    Time frame: 8 weeks

  6. The change in CGI-I and CGI-S total score from baseline

    Perform the Clinical Global Impression Scale (CGI-S) score from Visit 1 to Visit 7, and perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be.

    Time frame: 8 weeks

  7. The change in HAMA total score from baseline

    There are a total of 14 projects in Hamilton Anxiety Scale(HAMA), each with a 5-point scoring system ranging from 0 to 4 points. A total score of less than 6 on the scale is considered normal, a score of 7-14 indicates possible anxiety, a score of 15-20 indicates certain anxiety, a score of 21-28 indicates obvious anxiety, and a total score of more than 28 indicates severe anxiety. The higher the score, the more severe the anxiety.

    Time frame: 8 weeks

  8. The change in MADRS Single item score from baseline

    The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

  9. The change in HAMD-17 factor score from baseline

    The higher the score, the more severe the degree of depression.

    Time frame: 8 weeks

  10. The change in SHAPS total score from baseline

    There are a total of 14 projects in Snaith-Hamilton Pleasure Scale(SHAPS), each with a 4-point scoring system ranging from 1 to 4 points. Scores are distributed between 14-56 points. The higher the score, the more severe the anhedonia.

    Time frame: 8 weeks

07

Study locations

17 sites
  • Capital Medical University Affiliated Anding Hospital
    Beijing, Beijing Municipality, China
  • Peking University Sixth Hospital
    Beijing, Beijing Municipality, China
  • Chongqing 11th People's Hospital
    Chongqing, Chongqing Municipality, China
  • Chongqing Mental Health Center
    Chongqing, Chongqing Municipality, China
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Hebei Provincial Mental Health Center
    Baoding, Hebei, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Daqing Third Hospital
    Daqing, Heilongjiang, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu, China
  • Zhenjiang Mental Health Center
    Zhenjiang, Jiangsu, China
  • Jiangxi Provincial Psychiatric Hospital
    Nanchang, Jiangxi, China
  • Jilin Provincial Neuropsychiatric Hospital
    Siping, Jilin, China
  • Shandong Provincial Mental Health Center
    Jinan, Shandong, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin Municipality, China
  • Ürümqi Fourth People's Hospital
    Ürümqi, Xinjiang, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Huzhou Third People's Hospital
    Huzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Oct 2024, 9 months.

Of 54 industry-sponsored phase 2 interventional studies under Depression, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 29. This study's 9 months is below that.

Counting every sponsor, half of 198 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Dec 26, 2023
Primary completionActual
Oct 23, 2024
CompletionActual
Oct 23, 2024
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06259526
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Dec 26, 2023
Primary completion
Oct 23, 2024
Completion
Oct 23, 2024
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion